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S258 Poster Session IIpotentially reversibe risk factors could lessen the potentially disas-
trous results associated with CDAD.
Clostridium Difficile associated Disease
Characteristic CDAD postive CDAD negative p-valueNumber 83 739
age(range) 60(21-74) 56(18-78) .0687
sex(male/female) 37 444/295 0.410
Allo HSCT vs 30 177
Auto HSCT 53 562 .0232
Cefepime 64/83 496/739 .0831
Pip/Tazo 13/83 134/739 .651
Vancomycin 58/83 397/739 .0051
VRE surveillance positiv 29/83 140/739 .0014
Mortality 7/83 25/739 .0345271
ADENOVIRUS (ADV) INFECTION IN PEDIATRIC ALLOGENEIC STEM CELL
TRANSPLANTATION (ALLOSCT) RECIPIENTS IS A MAJOR INDEPENDENT
FACTOR FOR SIGNIFICANTLY INCREASING THE RISK OF TREATMENT RE-
LATED MORTALITY
El-Mallawany, N.K.1, George, D.1, Jin, Z.2, Della-Latta, P.3,
Satwani, P.1, Garvin, J.H.1, Bradley, M.B.1, Bhatia, M.1, van de
Ven, C.1, Morris, E.1, Schwartz, J.3, Cairo, M.S.1,3,4 1Morgan Stanley
Children’s Hospital, New York-Presbyterian, Columbia University, NY;
2Columbia University, New York, NY; 3Columbia University, New
York, NY; 4Columbia University, New York, NY
Background: ADV infection is an important cause of morbidity
following alloSCT in children, and the attributable mortality of
disseminated ADV in pediatric alloSCT recipients may exceed
80%. We sought to determine the incidence, risk factors, and
associated outcomes of ADV infection in pediatric AlloSCT re-
cipients.
Methods: We analyzed 123 consecutive pediatric AlloSCT recipi-
ents. Conditioning regimens were diverse; 59 (48%) received
reduced toxicity conditioning while 64 (52%) received a myeloabla-
tive regimen. Conditioning regimens included Alemtuzumab or
ATG in 24 (19.5%) and 65 (52.8%) patients respectively. GVHD
prophylaxis (tacrolimus and mycophenolate mofetil) and CMV pro-
phylaxis (alternating foscarnet and ganciclovir) were as previously
described (Osunkwo/Cairo et al, BBMT 2004; Shereck/Cairo et al,
PBC 2006). ADV was diagnosed by antigen detection or viral cul-
ture, and was defined by the isolation of virus with presence of cor-
relating clinical symptoms. Antigen detection was performed by
direct fluorescent assay from respiratory specimens and enzyme
immunoassay from stool.
Results: Age: median 9.5 (0.33–21 years), male/female: 71/52.
MFD 20%, MUD/UCBT 80%. Mean follow-up was 694 days.
The probability of developing ADV infection was 12.3% (CI95
6.0-18.6) and the median time to infection was 42 days (7-203
days). There were no statistically significant differences in proba-
bility of ADV infection in univariate analysis of risk factors includ-
ing donor source, use of ATG/Alemtuzumab, $ Grade II GVHD,
among others (age, diagnosis, conditioning regimen). The proba-
bility of overall survival (OS) for the entire cohort was 46.3%
(CI95 37.3-55.3). The probability of overall survival (OS) for pa-
tients that experienced ADV infection was 15.4% compared to
50% for those without ADV (p5 0.0286). In multivariate analysis,
several risk factors remained significant for an increased risk of
death including: ablative conditioning (HR 1.9), poor risk (HR
2.1), and most importantly, ADV infection (HR 3.15 [CI95 1.6-
6.18] p5 0.0009).
Conclusions: In this series of pediatric AlloSCT recipients, the de-
velopment of ADV infection was the leading multivariate predictor
of treatment-related mortality. Enhanced surveillance with ADV
PCR and identification of the risk factors associated with poor out-
comes from ADV infection may identify patients who could benefit
from pre-emptive therapeutic interventions including ADV-specific
cellular immunotherapies.272
ELEVATED SERUM LEPTIN LEVEL IN PATIENTS WITH PERSISTENT AN-
OREXIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION (ALLO-HSCT)
Kim, S.-W.1, Fuji, S.1, Fukuda, T.1, Mori, S.1, Kamiya, S.2, Furuta, K.3,
Yokoyama, H.1, Kurosawa, S.1, Saito, B.1, Kuwahara, S.2, Heike, Y.1,
Tanosaki, R.1, Takaue, Y.1 1National Cancer Center Hospital, Tokyo, Ja-
pan; 2National Cancer Center Hospital, Tokyo, Japan; 3National Cancer
Center Hospital, Tokyo, Japan
Background:Gastrointestinal toxicities, infections and GVHD are
common events among patients who undergo allo-HSCT. Leptin
is a hypothalamic modulator of food intake, and is secreted mainly
from adipose tissue. Additionally, it has been reported that circulat-
ing leptin levels increase during infection and inflammation, in-
cluding with autoimmune diseases. To examine whether leptin
may play a pathophysiological role in the early phase of HSCT,
we measured the serum level of leptin for correlation with clinical
parameters.
Methods: The serum level of leptin was measured using the ELISA
method in 67 patients (35 male, 32 female) who received allo-HSCT
from April 2006 to October 2007. The median age of the patients
was 48 years (range, 17-64). Allo-HSCT (42 BM, 20 PB, 5 cord
blood; 45 unrelated, 22 related) for hematologic diseases (31 AML,
21 lymphoma, 7 ALL, 8 others) was performed using myeloablative
(19 BU/CY, 17 CY/TBI6CA) or reduced-intensity conditioning
(14 Flu/BU/ATG-F 5-10 mg/kg, 9 Flu/BU/2-4 Gy TBI, 8 2CdA
or Flu/BU). GVHD prophylaxis was TAC-based in 45 patients
(67%) and CSP-based in 22 patients (33%). Fifty-eight patients
(87%) also received short-term MTX. We defined persistent an-
orexia as oral intake of less than 50% the basal energy expenditure
after 4 weeks post-HSCT. Fat mass was also measured using an In-
Body S20 body composition analyzer (Biospace Co., Ltd., Seoul,
Korea).
Results: The median levels of serum leptin before the conditioning
regimen, and at 1, 2 and 4 weeks after HSCT were, respectively,
4.4 mg/dL, 9.4 mg/dL, 7.8 mg/dL and 7.1 mg/dL. There was a sig-
nificant correlation between the pre-HSCT leptin level and pre-
HSCT body mass (r5 0.34, P5 0.005). The pre-HSCT leptin level
was higher in females than in males (median 5.4 mg/dL v 3.4 mg/dL,
P5 0.04). Pre-HSCT fat mass was recorded in 60 patients, and this
was significantly correlated with the pre-HSCT leptin level
(r5 0.63, P\0.001). There were 29 patients with persistent an-
orexia, and patients whose leptin level increased after HSCT
(n5 38) tended to have a higher incidence of persistent anorexia
(68% v 41%, P5 0.046). There was no correlation between the in-
cidence of acute GVHD and either the pre-HSCT leptin level or the
increase in leptin.
Conclusions: This study suggests that the elevation of leptin could
be associated with persistent anorexia after allo-HSCT. It may be
possible to develop an effective intervention against anorexia by sup-
pressing this leptin elevation.273
CYCLOSPORINE AREA UNDER THE CURVE (AUC) IN CHILDREN UNDER-
GOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT): LIM-
ITED SAMPLING STRATEGY (LSS)
Schechter, T.1, Teuffel, O.1, Gibson, P.1, Sung, L.1, Seto,W.2, Gassas, A.1,
Doyle, J.1, Dupuis, L.L.1,2 1The Hospital for Sick Children, Toronto, ON,
Canada; 2The Hospital for Sick Children, Toronto, ON, Canada
HSCT outcomes may be optimized by cyclosporine dose adjust-
ment according to systemic exposure (measured by AUC) rather
than trough concentration. We have developed LSSs for predicting
cyclosporine AUC after the initial IV dose in children undergoing
HSCT. The aim of this study was to validate the previously devel-
oped LSSs.
Children undergoing myeloablative HSCT and given cyclospor-
ine q12 h as a 2-hour infusion andmethotrexate/methylprednisolone
for acute GVHD prophylaxis were eligible. Cyclosporine AUC was
determined after the first dose and once weekly until engraftment us-
ing 9 concentration-time points.
The association between cyclosporine AUC using all available
data points (AUC-all) and the AUC values predicted by each LSS
was described using the adjusted coefficient of determination (r2);
Poster Session II S259values .0.9 were acceptable. Precision and mean bias\15% were
acceptable.
24 children (0.4-17.2 years) participated. Most patients (18) re-
ceived cyclosporine and methotrexate. Mean actual dose infusion
time was 1216 5.9 min. Mean AUC-all after the first cyclosporine
dose was 23976 713 hmg/L. Sufficient data were available to vali-
date the LSSs in 16 (3, 4 & 5-point LSSs) and 15 (6-point LSS) pa-
tients. Values of AUC predicted by all but the 5-point LSS were
strongly associated with AUC-all.
The 3-point LSS (2, 6 and 8 hours) is likely suitable for determin-
ing AUC following the first cyclosporine dose given as 2-hour infu-
sion to children undergoing HSCT. Further validation in a larger
number of patients is required. The relationship between acute
GVHD and cyclosporine AUC at different time periods after
HSCT merits further study.
Sample times Mean bias PrecisionAdjusted r2
(hours after start
of infusion) (%; range) (%)2, 6 and 8 0.9504 2 0.7 (213.7 to 12.4) 6.0
2, 2.5, 6 and 8 0.9547 22.7 (216.6 to 7.7) 6.0
2, 2.5, 4, 6 and 8 0.8896 24.7 (225.6 to 0.8) 9.1
2, 2.5, 4, 6, 8 and 10 0.9062 24.7 (224.2 to 20.1) 8.5274
KIDNEY INJURY (KI) IN PEDIATRIC RECIPIENTS OF ALLOGENEIC STEM
CELL TRANSPLANT (ALLOSCT): RISK OF KI IS GREATER WITH MYELOA-
BLATIVE CONDITIONING (MAC) THAN WITH REDUCED INTENSITY CON-
DITIONING (RIC) IN FIRST MONTH FOLLOWING ALLOSCT
Satwani, P.1, Bavishi, S.1, Jin, Z.2, Jacobson, J.S.3, Tallamy, B.1,
Cairo, M.S.1,4,5 1Columbia University, New York, NY; 2Columbia Uni-
versity, New York, NY; 3Columbia University, New York, NY; 4Colum-
bia University, New York, NY; 5Columbia University, New York, NY
Background:Pediatric alloSCTpatients are at substantial risk of de-
veloping KI, which contributes to transplant-related morbidity and
mortality (Holthe et al, Pediatr Nephrol., 2002).
Objective:To compare the incidence and outcomes of KI in pediat-
ric recipients following RIC vs. MAC AlloSCT in 1st year post-Al-
loSCT.
Methods: Among 170 pediatric patients, we used the Schwartz
equation to estimate creatinine clearance (eCCl) at# 2wks pre-
and 1,3,6,9 and 12 mo post-alloSCT with RIC orMAC.We catego-
rized patients whose eCCI dropped$ 50% from baseline as having
KI. Pts received Tacrolimus and MMF for GVHD prophylaxis
(Osunkwo/Cairo et al. BBMT, 2004). Other nephrotoxic exposures
included Ambisome at 3 mg/kg from day 0-100 (Roman/Cairo et al.
PBC, 2008) and CMV prophylaxis with Foscarnet/Ganciclovir
(Shereck/Cairo et al. PBC, 2007). Including risk factors significant
at 0.1 level based onc-square tests, we developedmultivariable logis-
tic regression models of predictors of kidney injury, and Cox models
of overall survival.
Results: 76 pts (median 10;0.3-22 yrs) receivedRIC-alloSCT; 94 pts
(median 8;0.3-22 yrs) receivedMA-AlloSCT. At 1 mo post alloSCT,
A total of43/94 (45.7%) MAC recipients but only 13/76 (17.1%)
RIC recipients had KI (p\0.0001). The two groups did not differ
in risk of KI at 3, 6, 9 or 12 months post-alloSCT. In univariate anal-
ysis, p-values were .0.1 for the association of KI at 1 mo with age,
sex, CMV at risk status, and fungal infections. Associations with
p-values #0.1were MAC (odds ratio {OR}-4.1, 95% CI 2.0-
8.4,p5 0.0001), poor disease risk status (OR-1.8,95% CI 0.8-4.0,
p5 0.1),VOD (OR-4.9, 95% CI 0.5-46.0, p5 0.1), and UCB
(OR-1.8,95% CI 0.9-3.6, p5 0.1). In logistic regression, only
MAC was an independent predictor of KI (OR-3.5, 95% CI 1.6-
7.7, p5 0.0001).
In the Cox model, all-cause mortality hazard ratios (HR) were:
RIC vs. MAC (HR5 0.3) p5 0.0007, poor vs. average risk disease
status (HR5 2.2) p5 0.002, UCB vs. MSD and MUD (HR-2.2)
p5 0.02, and KI vs. no KI (HR5 2.0) p5 0.006).Conclusions: In the firstmonth after alloSCT in children,MACwas
strongly associated with risk of KI, and overall, MAC and KI were
independent predictors of mortality. Avoiding KI in the first month
post-alloSCT might improve OS.275
SINGLE VS DOUBLE DOSE PALONOSETRON FOR THE PREVENTION OF
ACUTE AND DELAYED NAUSEA AND VOMITING IN PATIENTS UNDERGO-
ING HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANS-
PLANTATION
Marcacci, G., Becchimanzi, C., Capobianco, G., Arcamone, M.,
Corazzelli, G., Frigeri, F., Russo, F., Pinto, A. National Cancer Institute
‘‘Fondazione G. Pascale’’, Naples, Italy
Objectives:The vast majority of patients (pts) undergoing high dose
chemotherapy (HDT) and autologous stem cell transplantation
(ASCT) still experience major acute and delayed chemotherapy-in-
duced nausea and vomiting (CINV), showing how emesis control
in the ASCT setting remains sub-optimal. Palonosetron (PALO),
a new 5-hydroxytryptamine receptor antagonist with long half-life
and high receptor binding affinity, achieves a significant control of
CINV in pts receiving moderately/highly emetogenic chemother-
apy. We prospectively evaluated the efficacy of a single or double
i.v. dose PALO in pts undergoing HDT and ASCT.
Methods: A total of 60 pts (M/F5 32/28), median age 45 yrs (r16-
64), with diagnosis of lymphoma (29), myeloma (24), sarcoma (5),
acute leukemia (1), breast cancer (1) were accrued. The first cohort
(30 pts) received a single iv PALO dose (0.25 mg) plus 8 mg of dexa-
methasone (DMS) 30’ before starting of HDT while in the second
cohort (30 pts) the first dose was followed by a further PALO
(0.25 mg)/DMS (8 mg) injection 48 h after HDT. The distribution
of conditioning regimens (high-dose melphalan5 28, BEAM5 25,
MitoMel5 6, ThioEpiCTX5 1) was comparable between the two
cohorts. Acute (24 h) and delayed (120 h) CINV episodes were rated
by the visual analogic scale (MASCC/MAT) while CINV impact on
daily activities was self-assessed by pts (at 120 h from starting of
HDT), through the Functional Living Index-Emesis (FLIE) tool.
Results: No significant differences between the two groups (single
vs double PALO) emerged as to acute CINV evaluation (MAT) since
98% of pts achieved a complete response (CR5 no emesis, no need
for rescue therapy) with only 17 pts (28%) experiencing moderate
nausea (median intensity5 5, r1-10). Double-dose PALO displayed
a trend for a better control of delayed nausea which occurred in 53%
vs 77% of pts (p5 0.0581). In addition, double PALO dosing had
a highly significant impact on nausea-related modifications of daily
activities. FLIE nausea score was of a median value of 55.26
(r47.5-58.9) in pts receiving two doses of PALO vs 40.92 (r35-
45.2) for pts treated with the single PALO dosing (p5 0.0009).
Conclusion: Our results indicate that double dose PALO achieves
an optimal control of acute/delayed CINV and significantly reduces
the detrimental impact of nausea on daily activities in patients under-
going HDT. The impressive activity of PALO in the ASCT setting
might be possibly improved by combination with NK1 receptor an-
tagonists.276
END-OF-LIFE EXPERIENCE OF CHILDREN UNDERGOING STEM CELL
TRANSPLANTATION FOR MALIGNANCY: PARENT AND PROVIDER PER-
SPECTIVES AND PATTERNS OF CARE
Ullrich, C.K.1,2,3, Dussel, V.1,2,3, Hilden, J.M.3, Shaeffer, J.W.4,5,
Lehmann, L.1,3, Wolfe, J.1,2,3 1Dana-Farber Cancer Institute, Boston,
MA; 2Dana-Farber Cancer Institute, Boston, MA; 3Children’s Hospital,
Boston,MA; 4PeytonManning Children’s Hospital at St. Vincent, Indian-
apolis, IN; 5Children’s Hospitals and Clinics of Minnesota, St. Paul and
Minneapolis, MN
Background:The end-of-life (EOL) experience of childrenwho un-
dergo stem cell transplant (SCT), intensive therapy delivered with
curative intent, may differ from other children with cancer.
